Therapeutic resistance

Beginning in the July 2009 issue, Nature Reviews Cancer will be publishing a series of articles that take a look at different aspects of therapeutic resistance. Resistance to therapy — chemotherapy or radiotherapy — is an increasing problem in the care of patients with cancer. Numerous culprits have been identified, including environmental adaptations to therapy, aberrant regulation of drug transporters and signalling feedback loops that bypass targeted therapies. As discussed in the articles in this series, multi–targeted drugs, improved understanding of feedback regulation, pathway crosstalk and resistance mechanisms, as well as predictors of response all aim to overcome this significant challenge.


Top

2011

May 2011 Vol 11 No 5

Brain metastases as preventive and therapeutic targets

Patricia S. Steeg, Kevin A. Camphausen & Quentin R. Smith

May 2011 Vol 11 No 5

An analogy between the evolution of drug resistance in bacterial communities and malignant tissues

Guillaume Lambert, Luis Estévez-Salmeron, Steve Oh, David Liao, Beverly M. Emerson, Thea D. Tlsty & Robert H. Austin

2010

November 2010 Vol 10 No 11

Rational, biologically based treatment of EGFR–mutant non–small–cell lung cancer

William Pao & Juliann Chmielecki

March 2010 Vol 10 No 3

Microtubules and resistance to tubulin–binding agents

Maria Kavallaris

February 2010 Vol 10 No 2

Targeting the cancer kinome through polypharmacology

Zachary A. Knight, Henry Lin & Kevan M. Shokat

February 2010 Vol 10 No 2

ABC transporters in cancer: more than just drug efflux pumps

Jamie I. Fletcher, Michelle Haber, Michelle J. Henderson & Murray D. Norris

2009

September 2009 Vol 9 No 9

Biological determinants of endocrine resistance in breast cancer

Elizabeth A. Musgrove & Robert L. Sutherland

doi:10.1038/nrc2713

September 2009 Vol 9 No 9

Environment–mediated drug resistance: a major contributor to minimal residual disease

Mark B. Meads, Robert A. Gatenby & William S. Dalton

doi:10.1038/nrc2714

August 2009 Vol 9 No 8

CYP2D6 and tamoxifen: DNA matters in breast cancer

Janelle M. Hoskins, Lisa A. Carey & Howard L. McLeod

doi:10.1038/nrc2683

July 2009 Vol 9 No 7

Novel anticancer targets: revisiting ERBB2 and discovering ERBB3

José Baselga & Sandra M. Swain

doi:10.1038/nrc2656


Top